CAPR SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026

Capricor Therapeutics shares fell 64% to $7.00 on July 27, 2026 after FDA briefing documents said deramiocel's benefit-risk profile appeared unfavorable without evidence of effectiveness, then declined another 36% to $4.19 following an FDA advisory panel's 9-3 non-binding vote against efficacy for DMD-associated cardiomyopathy. Faruqi & Faruqi's proposed securities class action alleges Capricor changed its clinical-data statistical analysis plan without FDA agreement before resubmitting its BLA, while failing to disclose the resulting regulatory-approval risk. The putative class covers investors who acquired CAPR securities from December 17, 2025 through July 26, 2026, with a September 28, 2026 lead-plaintiff deadline.

Analysis

This is not a new fundamental catalyst; it is plaintiff-lawyer marketing following an already public regulatory failure. The incremental trading implication is therefore limited unless discovery produces evidence of deliberate protocol manipulation, undisclosed FDA correspondence, or a restatement-level governance issue. Litigation itself is unlikely to be a material cash claim against CAPR relative to the value destruction already driven by the program's regulatory outlook, but it can deter prospective equity financing and keep a governance discount embedded in the shares.

CAPR's near-term value is now dominated by FDA's final action, any path to a new controlled study, and the cash runway required to fund that path. A complete response or rejection would shift the company from an approval-duration story to a financing-duration story: dilution risk becomes nonlinear if management cannot identify a credible, FDA-agreed confirmatory design within 1-3 months. The key watch items are quarter-end cash, quarterly operating burn, any at-the-market usage, and whether the agency identifies remediable evidentiary gaps versus requiring a new efficacy trial.

Consensus may overestimate the informational value of the lawsuit because securities actions commonly follow large biotech drawdowns. Conversely, the market may still underprice the practical cost of a new DMD cardiomyopathy study: enrollment, endpoint validation, and follow-up could push meaningful commercialization several years out, lowering the probability-weighted value of the asset even if a resubmission route remains available. CAPR could rally sharply on any constructive FDA communication, but absent that, post-event volatility and liquidity make a clean directional short unattractive after the collapse.

Key Decisions for Investors

• No new outright CAPR short solely on this lawsuit; treat it as non-incremental information. Reassess after the next cash/burn disclosure and FDA decision, when dilution probability can be quantified.
• For existing CAPR exposure, reduce risk into any litigation-driven bounce unless management provides an FDA-aligned remediation plan with a defined study design and funding source; a final rejection or new pivotal-trial requirement falsifies any near-term recovery thesis.
• Set an alert for an equity raise, ATM prospectus supplement, or cash runway below 12 months. Those events would support renewed downside positioning over the following 1-3 months, preferably via puts or a defined-risk put spread given binary regulatory headline risk.
• Monitor Sarepta (SRPT) and broader rare-disease biotech ETFs such as XBI only for sentiment spillover; CAPR-specific evidentiary concerns do not presently establish a transferable read-through to DMD peers.